422 related articles for article (PubMed ID: 19785509)
1. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
Merkel RL; Kuchibhatla A
Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
[TBL] [Abstract][Full Text] [Related]
2. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
4. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
5. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
Faraone SV; Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
[TBL] [Abstract][Full Text] [Related]
6. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
7. Childhood stimulant treatment and risk for later substance abuse.
Fischer M; Barkley RA
J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
[TBL] [Abstract][Full Text] [Related]
8. Dexmethylphenidate for attention deficit hyperactivity disorder.
Coury D
Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
[TBL] [Abstract][Full Text] [Related]
9. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
10. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
Kollins SH
J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623
[TBL] [Abstract][Full Text] [Related]
11. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
Janols LO; Liliemark J; Klintberg K; von Knorring AL
Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
[TBL] [Abstract][Full Text] [Related]
12. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
13. Attention deficit hyperactivity disorder and substance use disorders.
Szobot CM; Bukstein O
Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
[TBL] [Abstract][Full Text] [Related]
14. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
Kollins SH
J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
[TBL] [Abstract][Full Text] [Related]
15. Naturalistic long-term use of methylphenidate in bipolar disorder.
Lydon E; El-Mallakh RS
J Clin Psychopharmacol; 2006 Oct; 26(5):516-8. PubMed ID: 16974196
[TBL] [Abstract][Full Text] [Related]
16. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
[No Abstract] [Full Text] [Related]
17. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
Biederman J
J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
[TBL] [Abstract][Full Text] [Related]
19. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
Torres AR; Whitney J; Gonzalez-Heydrich J
Epilepsy Behav; 2008 Feb; 12(2):217-33. PubMed ID: 18065271
[TBL] [Abstract][Full Text] [Related]
20. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
